Quest Diagnostics DS revenues — Total net revenues, percent remained flat by 0.0% to 0.5% in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 33.3%, from 0.8% to 0.5%. Over 4 years (FY 2021 to FY 2025), DS revenues — Total net revenues, percent shows a downward trend with a -9.6% CAGR.
An increase suggests the Diagnostic Solutions segment is growing faster than the core clinical testing business, indicating successful diversification or expansion into specialized services. A decrease suggests the core clinical testing business is outpacing the growth of the Diagnostic Solutions segment.
This metric represents the proportion of total consolidated net revenues generated by the Diagnostic Solutions segment....
Peers in the diagnostic and life sciences sector often report similar segment-level revenue contributions, typically ranging from low single digits to mid-teens depending on the company's focus on clinical trial support versus core diagnostic testing.
dgx_segment_ds_revenues_total_net_revenues_percent| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | 3% | 3% | 3% | 3% | 2% |
| YoY Change | — | +0.0% | +0.0% | +0.0% | -33.3% |